The third-place slot marked another return to form. Novo Nordisk’s Wegovy reclaimed the seat it held in December, backed by ...

The FDA approved Bimzelx, an IL-17A/IL-17F inhibitor, for use in active PsA in September ... were higher for Bimzelx than for Rinvoq and Skyrizi and Johnson & Johnson’s Tremfya at the same ...

Skyrizi – partnered with Boehringer Ingelheim ... He added that the data contributed “to the whole of evidence supporting risankizumab use in moderate to severe plaque psoriasis.” ...

Skyrizi (risankizumab ... study called INSPIRE and a 52-week maintenance study called COMMAND. The new use in adults with moderately to severely active UC makes the drug an option for some ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ... a positive recommendation for AbbVie’s ulcerative colitis drug Skyrizi ...

(RTTNews) - AbbVie Inc. (ABBV) Tuesday said that its Skyrizi approved for the treatment of adults with moderately to severely active ulcerative colitis is now available in Canada. Ulcerative ...

The North Chicago drugmaker said in a press release today the European Medicines Agency's Committee for Medicinal Products for Human Use ... anti-inflammatory drug Skyrizi following the loss ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended ... for AbbVie’s ulcerative colitis drug Skyrizi (risankizumab). "CHMP recommends AbbVie ...